Methionine enkephalin regulates microglia polarization and function

Xuxu Xu1, Yan Gao1, Lulu Wen1

  • 1Department of Neurology, Shengjing Hospital, Affiliated Hospital of China Medical University, Shenyang 110004, PR China.

Insights

Methionine enkephalin (MENK) promotes microglia to an M1 phenotype, enhancing their tumoricidal activity against glioblastoma. This opioid peptide shows potential for modulating anti-tumor immunity in the central nervous system.

Area of Science:

  • Neuroimmunology
  • Cancer Immunology

Background:

  • Microglia are key immune cells in the central nervous system (CNS).
  • Methionine enkephalin (MENK) is an opioid peptide that regulates immune responses.

Purpose of the Study:

  • To investigate the effect of MENK on microglia polarization.
  • To assess MENK's impact on microglia's tumoricidal responses against glioblastoma.

Main Methods:

  • Treatment of microglia with MENK (10-12M for 48h).
  • Analysis of M1/M2 marker gene expression (CD86, CD40, IL-12, TNF-α, CD163, IL-10, TGF-β).
  • Assessment of phagocytosis, reactive oxygen species (ROS), nitric oxide (NO) production, and cytotoxicity against glioblastoma cells.

Main Results:

  • MENK induced an M1 microglia phenotype, upregulating M1 markers and phagocytosis.
  • MENK increased ROS and NO production (via iNOS) without affecting M2 markers or arginase-1.
  • MENK-treated microglia exhibited significant cytotoxicity against glioblastoma cells.

Conclusions:

  • MENK drives microglia towards an M1 phenotype, enhancing anti-tumor immunity.
  • MENK demonstrates potential as a therapeutic agent for glioblastoma by activating microglia-mediated tumoricidal activity.

Related Concept Videos